CN112076265A - Traditional Chinese medicine composition for treating neonatal jaundice and application thereof - Google Patents
Traditional Chinese medicine composition for treating neonatal jaundice and application thereof Download PDFInfo
- Publication number
- CN112076265A CN112076265A CN202010951309.4A CN202010951309A CN112076265A CN 112076265 A CN112076265 A CN 112076265A CN 202010951309 A CN202010951309 A CN 202010951309A CN 112076265 A CN112076265 A CN 112076265A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- traditional chinese
- radix
- root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Insects & Arthropods (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The traditional Chinese medicine composition for treating neonatal jaundice provided by the embodiment of the application is characterized by being prepared from the following raw material medicines in parts by weight: 10 parts of figwort root, 10 parts of dried rehmannia root, 10 g of phellodendron bark, 9 to 15 parts of baical skullcap root, 10 parts of oriental wormwood, 10 parts of forsythia, 7 to 15 parts of honeysuckle flower, 5 to 20 parts of pittosporum fruit, 5 to 10 parts of Mongolian snakegourd root, parts of silkworm and 10 parts of raw liquoric root. The traditional Chinese medicine compound preparation has the advantages that the raw materials are common traditional Chinese medicines, the traditional Chinese medicine compound preparation is simple and low in cost, and the traditional Chinese medicine compound preparation has obvious curative effect on intrahepatic cholestatic jaundice through years of clinical application and pharmacological research, and has wide market prospect.
Description
Technical Field
The invention relates to a traditional Chinese medicine composition, belongs to the field of traditional Chinese medicine preparations, and particularly relates to a traditional Chinese medicine composition for treating neonatal jaundice and application thereof.
Background
Neonatal jaundice is one of the most common manifestations during the neonatal period. Normal adult serum bilirubin is lower than 17 mu mol/L (1mg/dl), and jaundice can occur when the serum bilirubin exceeds 34 mu mol/L (2 mg/dl). Newborn infants have visible jaundice when serum bilirubin exceeds 85 μmol/L (5mg/dl) due to abundant capillaries. Unconjugated bilirubin elevation is the most common manifestation of neonatal jaundice. Because of the metabolic characteristics of bilirubin in the newborn, if bilirubin encephalopathy can be caused by untimely treatment, the nervous system can be permanently damaged and even die, the health and the life of the newborn are seriously threatened, and the statistical result shows that: jaundice occurs in approximately 60% of newborns.
Neonatal jaundice is generally classified into physiological jaundice and pathological jaundice, and the physiological jaundice is generally good; pathological jaundice has many etiologies, and generally has three types: 1) excessive bilirubin production; 2) Liver bilirubin metabolism disorder; 3) bilirubin excretion disorder. According to clinical manifestations and the current technology, neonatal jaundice is easy to diagnose. Phototherapy and liver enzyme inducer medicine are used for treatment.
Pathological jaundice, the main safer treatment modality at present, is blue light irradiation therapy, and the drawbacks of phototherapy are: 1. the regression of skin jaundice after phototherapy does not indicate that serum non-conjugated bilirubin is normal, so jaundice is easy to repeat after phototherapy, and jaundice is essentially caused by the increase of serum bilirubin. Therefore, phototherapy cannot fundamentally reduce serum bilirubin and cannot substantially treat jaundice. 2. Side effects: fever, diarrhea and rash can occur, but are not severe enough, phototherapy can be continued, riboflavin in a body can be decomposed by blue light, and the phototherapy can cause riboflavin reduction after more than 24 hours, so that the activity of erythrocyte glutathione reductase is reduced, and hemolysis is aggravated. Phototherapy and liver enzyme inducer, high treatment cost, insignificant effect and high recurrence rate.
Jaundice is called as jaundice and jaundice in traditional Chinese medicine, and is a disease which is mainly characterized by yellowing of leucorrhea in eyes of the whole body after newborn birth, and the disease is caused and pathogenesis of damp-heat fumigation, cold-temperature retardation and yellow stasis accumulation. The existing traditional Chinese medicine preparation has no obvious treatment effect and no effective treatment medicine.
Disclosure of Invention
In view of the above, the present application aims to provide a traditional Chinese medicine composition for effectively treating neonatal jaundice. In order to achieve the purpose, the technical scheme adopted by the application is as follows: a traditional Chinese medicine composition for treating neonatal jaundice is prepared from the following raw material medicines in parts by weight:
10 parts of figwort root, 10 parts of dried rehmannia root, 10 g of phellodendron bark, 9 to 15 parts of baical skullcap root, 10 parts of oriental wormwood, 10 parts of forsythia, 7 to 15 parts of honeysuckle flower, 5 to 20 parts of pittosporum fruit, 5 to 10 parts of Mongolian snakegourd root, parts of silkworm and 10 parts of raw liquoric root.
As recorded in Ben Cao gang mu, Yin Chen is the essential herb for treating jaundice. Modern Chinese pharmacology research shows that artemisia capillaris thunb extracted from artemisia capillaris has the function of promoting bilirubin excretion, and on the background, the inventor successfully finds that the medicine property is milder and is more suitable for new-born medication through the synthesis of radix scrophulariae, radix rehmanniae, phellodendron, radix scutellariae, forsythia, honeysuckle, gardenia jasminoides, trichosanthes root, silkworm and raw liquorice. The traditional Chinese medicine composition disclosed by the invention has a remarkable effect on treating neonatal jaundice, particularly on pathological jaundice, and is low in side effect and good in stability. Meanwhile, the traditional Chinese medicine composition has the same treatment effect on physiological jaundice.
Preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight:
10 parts of radix scrophulariae, 10 parts of radix rehmanniae, 10 g of golden cypress, 9 parts of radix scutellariae, 10 parts of herba artemisiae scopariae, 10 parts of forsythia, 6 parts of honeysuckle, 5 parts of fructus gardeniae, 5 parts of radix trichosanthis, parts of silkworm and 10 parts of raw liquorice.
Preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight:
10 parts of radix scrophulariae, 10 parts of radix rehmanniae, 10 g of golden cypress, 15 parts of radix scutellariae, 10 parts of herba artemisiae scopariae, 10 parts of forsythia, 15 parts of honeysuckle, 20 parts of fructus gardeniae, 10 parts of radix trichosanthis, parts of silkworm and 10 parts of raw liquorice.
Preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight:
10 parts of radix scrophulariae, 10 parts of radix rehmanniae, 10 g of golden cypress, 10 parts of radix scutellariae, 10 parts of herba artemisiae scopariae, 10 parts of forsythia, 10 parts of honeysuckle, 10 parts of fructus gardeniae, 7 parts of radix trichosanthis, parts of silkworm and 10 parts of raw liquorice.
On the other hand, the application aims to provide the application of the traditional Chinese medicine composition in preparing the medicine for treating neonatal jaundice.
Further, the traditional Chinese medicine composition also comprises pharmaceutically acceptable auxiliary materials.
Further, the traditional Chinese medicine composition is decoction, tablets, capsules, granules, mixture, oral liquid or syrup.
The invention has the beneficial effects that:
1. the traditional Chinese medicine composition of the invention shows that the medicine is safe to use, and does not cause adverse reaction when taken in a safe range; has no toxic and side effects on skin.
2. The traditional Chinese medicine composition has the effect of promoting bilirubin to be discharged out of the body, and the elimination of the skin jaundice shows that the serum bilirubin reaches the normal range, so that the illness state of the infant patient is effectively controlled, the recurrence rate of the neonatal jaundice is extremely low after the elimination, and the curative effect is definite.
3. Clinical observation shows that the total effective rate of the traditional Chinese medicine composition reaches more than 85.3 percent. But has no obvious curative effect on obstructive jaundice and congenital jaundice.
4. The Chinese medicinal composition is convenient and safe to use, does not need mother-baby separation, is beneficial to mother-baby communication of neonates, is beneficial to cultivating mother-baby emotion, enables the neonates to have a safe feeling, and is beneficial to growth.
5. The product has the advantages of wide medicine source, simple preparation processing, economic price, safe and effective clinical application, good stability, easy acceptance by patients and convenient popularization.
6. The invention successfully treats two cases of children with failed hearing test caused by hyperbilirubinemia, effectively reduces bilirubin in time through timely treatment, and rechecks the hearing of children with family patients in a hospital II after one month, and is proved to be recovered. Although the inventors cannot exclude the accidental factor at present for sample reasons, the inventors provide a medicine research basis for the treatment of bilirubin encephalopathy.
Detailed Description
The present application will be described in further detail with reference to examples. It is to be understood that the specific embodiments described herein are merely illustrative of the relevant invention and not restrictive of the invention.
The embodiment of the application provides a traditional Chinese medicine composition for treating neonatal jaundice, which is prepared from the following raw material medicines in parts by weight:
10 parts of figwort root, 10 parts of dried rehmannia root, 10 g of phellodendron bark, 9 to 15 parts of baical skullcap root, 10 parts of oriental wormwood, 10 parts of forsythia, 7 to 15 parts of honeysuckle flower, 5 to 20 parts of pittosporum fruit, 5 to 10 parts of Mongolian snakegourd root, parts of silkworm and 10 parts of raw liquoric root.
Example 1
10 parts of radix scrophulariae, 10 parts of radix rehmanniae, 10 g of golden cypress, 9 parts of radix scutellariae, 10 parts of herba artemisiae scopariae, 10 parts of forsythia, 6 parts of honeysuckle, 5 parts of fructus gardeniae, 5 parts of radix trichosanthis, parts of silkworm and 10 parts of raw liquorice.
Example 2
10 parts of radix scrophulariae, 10 parts of radix rehmanniae, 10 g of golden cypress, 15 parts of radix scutellariae, 10 parts of herba artemisiae scopariae, 10 parts of forsythia, 15 parts of honeysuckle, 20 parts of fructus gardeniae, 10 parts of radix trichosanthis, parts of silkworm and 10 parts of raw liquorice.
Example 3
10 parts of radix scrophulariae, 10 parts of radix rehmanniae, 10 g of golden cypress, 10 parts of radix scutellariae, 10 parts of herba artemisiae scopariae, 10 parts of forsythia, 10 parts of honeysuckle, 10 parts of fructus gardeniae, 7 parts of radix trichosanthis, parts of silkworm and 10 parts of raw liquorice.
Example 4
10 parts of radix scrophulariae, 10 parts of radix rehmanniae, 10 g of golden cypress, 10 parts of radix scutellariae, 10 parts of herba artemisiae scopariae, 10 parts of forsythia, 12 parts of honeysuckle, 12 parts of fructus gardeniae, 9 parts of radix trichosanthis, parts of silkworm and 10 parts of raw liquorice.
Example 5
10 parts of radix scrophulariae, 10 parts of radix rehmanniae, 10 g of golden cypress, 10 parts of radix scutellariae, 10 parts of herba artemisiae scopariae, 10 parts of forsythia, 13 parts of honeysuckle, 14 parts of fructus gardeniae, 8 parts of radix trichosanthis, parts of silkworm and 10 parts of raw liquorice.
Example 6
Preparation of a Chinese medicinal composition decoction: weighing the raw materials according to the mixture ratio of any one of embodiments 1-5, adding 3 times of water, soaking for 2 hours, decocting for 2 times, and each time for 1.5 hours to obtain the traditional Chinese medicine composition decoction.
Example 7
Preparation of Chinese medicinal composition tablets/capsules: weighing the raw materials according to the proportion of any one of embodiments 1-5, adding 3 times of water, soaking for 2 hours, decocting for 2 times, 1.5 hours each time, concentrating under reduced pressure to obtain extract, vacuum drying the extract to prepare traditional Chinese medicine extract powder, adding a proper amount of auxiliary materials, granulating by a dry method to prepare granules, and pressing into tablets or filling into capsules.
Example 8
Preparing the traditional Chinese medicine composition granules: weighing the raw materials according to the proportion of any one of embodiments 1-5, adding 3 times of water, soaking for 2 hours, decocting for 2 times, each time for 1.5 hours, concentrating under reduced pressure to obtain extract, vacuum drying the extract to prepare traditional Chinese medicine extract powder, adding a proper amount of auxiliary materials, and granulating by a dry method to prepare granules.
Example 9
Preparation of traditional Chinese medicine composition mixture/oral liquid/syrup: weighing the raw materials according to the mixture ratio of any one of embodiments 1-5, adding 3 times of water, soaking for 2 hours, decocting for 2 times, each time for 1.5 hours, adding appropriate pharmaceutical adjuvants (white sugar, honey, benzyl propionic acid or ethylparaben, etc.), and making into mixture, oral liquid or syrup.
Example 10 Effect of the invention on intrahepatic cholestasis rat model
(1) Intrahepatic cholestasis animal model
Healthy male SD rats 140 were selected, weighing 150-. Dissolving ANIT 1g in 50ml sesame oil (heating) to make into 2% W/V, and administrating 100mg/kg (5ml/kg) of the normal group and the rest groups at one time to induce intrahepatic cholestasis animal model. Divided into 7 groups of 20.
(2) Experimental grouping and treatment methods
1, Normal control group
2, intrahepatic cholestasis model control group
3, Western medicine group (ursodeoxycholic acid)
4, Chinese medicine one (example 1) (for Chinese medicine compound 50mg/kg intragastric administration)
5, Chinese medicine two (example 3) (for Chinese medicine compound 50mg/kg intragastric administration)
6, Chinese medicine three (example 5) (for Chinese medicine compound 50mg/kg intragastric administration)
7, Chinese medicine control group I (20 parts of Artemisia capillaris, 10 parts of red peony root, 10 parts of bupleurum root, 20 parts of salvia miltiorrhiza, 15 parts of prepared rhubarb, 10 parts of fried bighead atractylodes rhizome, 20 parts of plantain seed and 7 parts of dandelion) (for Chinese medicine compound 50mg/kg intragastric administration)
The western medicine group is administrated by gastric lavage with ursodeoxycholic acid 50mg/kg, and other groups are administrated by gastric lavage with normal saline of the same volume according to the conversion of rat weight for 1 time every day. 10 rats were sacrificed at 3d and 5d each, blood, bile and liver tissue samples were collected, and the changes of the following indices were observed.
(3) Detecting items
Biochemical indexes of serum: serum alanine Aminotransferase (ALT), serum alkaline phosphatase (ALP), serum Total Bilirubin (TBIL), serum Direct Bilirubin (DBIL), serum Total Bile Acid (TBA);
second, the examination of liver tissue by optical microscope and electron microscope.
(4) Results of the experiment
Firstly, biochemical index detection of each group of rat serum
Compared with the model group, the indexes of the traditional Chinese medicine group I and the traditional Chinese medicine group II are reduced, and the difference has statistical significance.
Group ALT AKP TBIL DBIL TBA
Normal group 45.35 + -6.75335.15 + -62.751.97 + -1.311.47 + -1.158.78 + -2.32
Model group 178.35 + -22.09565.45 + -38.86108.13 + -21.4599.75 + -23.40178.66 + -23.34
Western medicine group 101.04 + -23.53423.40 + -11.6888.23 + -17.1285.45 + -12.04135.80 + -26.35
Group of Chinese medicines 105.35 + -15.15435.50 + -12.2389.33 + -16.1286.01 + -11.29144.36 + -25.45
The two groups of Chinese medicines are 104.27 + -14.85426.50 + -11.1487.76 + -15.4285.87 + -10.89147.26 + -23.31
106.16 + -14.95441.50 + -13.0388.43 + -17.0186.53 + -11.45145.47 + -24.66 of the three groups of Chinese medicines
The Chinese medicine control group 115.35 + -15.15455.50 + -12.23106.33 + -16.1298.01 + -11.29164.36 + -25.45
The liver cells of the normal group of rats are regularly arranged, and the portal area has no obvious lesion; the liver lobules of the rat in the model group are damaged, a large amount of inflammatory cells in the portal area are infiltrated, small bile ducts are proliferated, and mild fibroplasia is caused; the western medicine group rats are similar, and only a small amount of inflammatory cell infiltration is seen in the portal area; similar to the rats in the traditional Chinese medicine group, only a small amount of inflammatory cell infiltration is seen in the portal area.
EXAMPLE 11 clinical study of the present application
Zhou somewhat, male, 37 years old, North Hebei Yansuburb. Initial diagnosis date: 11/3/2019. The patient will be diagnosed with "yellow skin and urine, anorexia with paroxysmal abdominal pain for 2 months". The patient has no obvious reasons of chilliness and fever 2 months ago, the body temperature is as high as 38.7 ℃, and the patient has skin itch, abdominal distension and pain, no nausea, vomiting and no white stool. Day 11, 4 to local hospital examination. Liver function: TBIL: 347.9mmol/L, DBIL: 254.6mmol/L, ALT: 55.1U/L, ALP: 307.3U/L, all viral hepatitis indexes are normal. MRI: multiple cholecystolithiasis, cholecystitis, cholecystolithiasis, dilatation of gallbladder duct, and mild dilatation of intrahepatic duct. Local meridians protect liver and reduce enzyme, and cure jaundice without obvious improvement, and jaundice further aggravates. Liver function at 11 months and 13 days: TBIL: 405.1mmol/L, DBIL: 388.7mmol/L, 48.0g/L total protein, 29.0g/L albumin, AST 47.0U/L, 298.0U/L ALP, and 212.7mmol/L total bile acid. The patients and their families go to our hospital for treatment. The method comprises the following steps: yellow sclera and skin, anorexia, nausea, vomiting after eating, general skin pruritus, lower abdominal distending pain; yellow urine and normal stool; poor sleep, lassitude; no liver palm and spider nevus; the abdomen is soft and the lower costal region of the liver and spleen is not reached; no tenderness, rebound pain and moving voice of abdomen. Dark tongue with ecchymosis, yellow and greasy coating, and wiry and slippery pulse. Is used for treating damp-heat, jaundice, and blood circulation promoting. The prescription is as follows: 10 parts of radix scrophulariae, 10 parts of radix rehmanniae, 10 g of golden cypress, 10 parts of radix scutellariae, 10 parts of herba artemisiae scopariae, 10 parts of forsythia, 13 parts of honeysuckle, 14 parts of fructus gardeniae, 8 parts of radix trichosanthis, parts of silkworm and 10 parts of raw liquorice. After taking for 1 week, jaundice is relieved, appetite is improved, nausea symptom is not obvious, systemic pruritus is relieved, and excrement is thin, and 3 times a day. Liver function: TBIL: 278.1mmol/L, DBIL: 224.7mmol/L, 49.5g/L total protein, 30.0g/L albumin, 30.0U/L ALT/LAST 40.0U/L ALP:198.0U/L ALP, 112.7mmol/L total bile acid. On the basis of the above formula, the prepared rhubarb is reduced to 9g, the bighead atractylodes rhizome is increased to 45g, and the red paeony root is reduced to 60 g. After taking the medicine for 3 weeks, jaundice is continuously improved, no obvious pruritus exists, appetite is general, nausea and vomiting do not exist, stool and excrement are normal, urine is yellow, and strength is increased. And (4) rechecking TBIL: 51.1mmol/L, DBIL: 29.7 mmol/L. For the three diagnostic methods, 30g of Bai Zhu is adjusted. TBIL after 2 weeks of administration: 18.1mmol/L, DBIL: 6.1 mmol/L. The remaining indicators are basically normal. After 2 weeks, the liver function was rechecked half a year later, and the index was normal.
Example 12 clinical study of the invention
Zhangqi, male, age 32, Shanxi. The physician can see the disease in 5 months in 2019 and make a first diagnosis. The history of hepatitis B is 20 years later, the period is as follows: yellow staining of skin and sclera, yellow urine for 2 days. The patients have no obvious induction before 2 days, and have the symptoms of yellow skin and sclera, yellow urine, dull pain of lower abdomen, clear spirit, mild appetite, sleep, no nausea, vomiting, fever, lumbago, constipation, dark tongue, white and greasy tongue coating and wiry and smooth pulse. Biochemical detection in our hospital suggests TBIL: 130.1mmo/L, DBIL: 105.8 mmol/L. Is used for treating damp-heat, jaundice, and blood circulation promoting. The prescription is as follows: 10 parts of radix scrophulariae, 10 parts of radix rehmanniae, 10 g of golden cypress, 10 parts of radix scutellariae, 10 parts of herba artemisiae scopariae, 10 parts of forsythia, 13 parts of honeysuckle, 14 parts of fructus gardeniae, 8 parts of radix trichosanthis, parts of silkworm and 10 parts of raw liquorice. After 2 weeks of administration, jaundice is obviously relieved, urine is yellowish, lower abdomen is still dull, painful and uncomfortable, and excrement is normal. 15g of rhizoma corydalis Decumbentis is added above the powder for 2 weeks, and bilirubin is checked to be normal.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and additions can be made without departing from the method of the present invention, and these modifications and additions should also be regarded as the protection scope of the present invention.
Claims (7)
1. The traditional Chinese medicine composition for treating neonatal jaundice is characterized by being prepared from the following raw material medicines in parts by weight:
10 parts of figwort root, 10 parts of dried rehmannia root, 10 g of phellodendron bark, 9 to 15 parts of baical skullcap root, 10 parts of oriental wormwood, 10 parts of forsythia, 7 to 15 parts of honeysuckle flower, 5 to 20 parts of pittosporum fruit, 5 to 10 parts of Mongolian snakegourd root, parts of silkworm and 10 parts of raw liquoric root.
2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight:
10 parts of radix scrophulariae, 10 parts of radix rehmanniae, 10 g of golden cypress, 9 parts of radix scutellariae, 10 parts of herba artemisiae scopariae, 10 parts of forsythia, 6 parts of honeysuckle, 5 parts of fructus gardeniae, 5 parts of radix trichosanthis, parts of silkworm and 10 parts of raw liquorice.
3. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight:
10 parts of radix scrophulariae, 10 parts of radix rehmanniae, 10 g of golden cypress, 15 parts of radix scutellariae, 10 parts of herba artemisiae scopariae, 10 parts of forsythia, 15 parts of honeysuckle, 20 parts of fructus gardeniae, 10 parts of radix trichosanthis, parts of silkworm and 10 parts of raw liquorice.
4. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight:
10 parts of radix scrophulariae, 10 parts of radix rehmanniae, 10 g of golden cypress, 10 parts of radix scutellariae, 10 parts of herba artemisiae scopariae, 10 parts of forsythia, 10 parts of honeysuckle, 10 parts of fructus gardeniae, 7 parts of radix trichosanthis, parts of silkworm and 10 parts of raw liquorice.
5. The use of the Chinese medicinal composition according to any one of claims 1 to 4 for the preparation of a medicament for the treatment of neonatal jaundice.
6. The use of claim 5, wherein the Chinese medicinal composition further comprises pharmaceutically acceptable excipients.
7. The use of claim 5, wherein the Chinese medicinal composition is in the form of decoction, tablet, capsule, granule, mixture, oral liquid or syrup.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010951309.4A CN112076265A (en) | 2020-09-11 | 2020-09-11 | Traditional Chinese medicine composition for treating neonatal jaundice and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010951309.4A CN112076265A (en) | 2020-09-11 | 2020-09-11 | Traditional Chinese medicine composition for treating neonatal jaundice and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112076265A true CN112076265A (en) | 2020-12-15 |
Family
ID=73737445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010951309.4A Pending CN112076265A (en) | 2020-09-11 | 2020-09-11 | Traditional Chinese medicine composition for treating neonatal jaundice and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112076265A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1706442A (en) * | 2005-05-30 | 2005-12-14 | 许建文 | Prepn process of medicine for treating icteric diseases and oral liquid containing the medicine |
-
2020
- 2020-09-11 CN CN202010951309.4A patent/CN112076265A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1706442A (en) * | 2005-05-30 | 2005-12-14 | 许建文 | Prepn process of medicine for treating icteric diseases and oral liquid containing the medicine |
Non-Patent Citations (2)
| Title |
|---|
| 沈笑梅等: "中西医结合治疗母乳性黄疸98例临床观察", 《西部医学》 * |
| 王先英: "中药治疗新生儿病理性黄疸之体会", 《内蒙古中医药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03003446A (en) | Novel medicinal herbal composition for treating liver diseases and hiv. | |
| JP2004161732A (en) | Natural medicine preparation for treatment of hiv/aids patient | |
| CN102284050B (en) | Chinese medicine composition for treating infertility caused by cold uterus | |
| CN103285119B (en) | Chinese medicine composition for treating autoimmune liver disease, and preparation method thereof | |
| CN102526566B (en) | Chinese medicine preparation for treating hysteromyoma and ovaricyst and preparation method | |
| CN1329047C (en) | Chinese medicinal composition for treating acute icterohepatitis | |
| CN101513488B (en) | Traditional Chinese medicine compound for treating hepatitis | |
| CN103169883B (en) | Traditional Chinese medicine for treating infantile jaundice | |
| CN109718317B (en) | Traditional Chinese medicine composition for treating ulcerative colitis | |
| CN104815243A (en) | Preparation method of external washing liquid for atrophic vaginitis | |
| CN103301353B (en) | Pharmaceutical composition for treating atrophic vaginitis | |
| CN103285284B (en) | Medical composition for treating senile vaginitis | |
| CN104857436A (en) | Chinese herbal compound composition with anti-hepatoma activity as well as preparation method and application of Chinese herbal compound composition | |
| CN115227795A (en) | Compound medicine for treating HPV persistent infection and preparation method and application thereof | |
| CN112076265A (en) | Traditional Chinese medicine composition for treating neonatal jaundice and application thereof | |
| CN101264218A (en) | Medicaments assembly for clearing heat and removing dampness, smoothing liver and invigorating spleen and preparation thereof | |
| CN101116683B (en) | Medicine for treating arthritis | |
| CN112190681A (en) | Traditional Chinese medicine composition for treating ulcerative colitis and preparation method thereof | |
| CN101461857A (en) | Medicament for treating severe hepatitis | |
| CN114632127B (en) | Traditional Chinese medicine composition and preparation for treating pediatric jaundice as well as preparation method and application of traditional Chinese medicine composition and preparation | |
| CN1233383C (en) | Chinese medicinal preparation for treating prostate disease and its preparation method | |
| CN102961555B (en) | Traditional Chinese medicine composition for treating liver diseases and preparation method for same | |
| CN116350731B (en) | Formula for clearing heat, removing dampness and relieving arthralgia as well as preparation and application thereof | |
| CN107184651B (en) | Traditional Chinese medicine composition for clearing away heat and toxic materials and preparation method and application thereof | |
| CN102309725B (en) | Traditional Chinese medicine preparation for treating hepatitis B cirrhosis and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201215 |
|
| RJ01 | Rejection of invention patent application after publication |